Patients' preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine

被引：12

作者：

Dowson A.J. ^{[1
]}

Tepper S.J. ^{[2
]}

Dahlöf C. ^{[3
]}

机构：

[1] King's Headache Service, King's College Hospital, London SE5 9RS, Denmark Hill

[2] The New England Center for Headache, Stamford, CT

[3] Gothenburg Migraine Clinic, Gothenburg

来源：

The Journal of Headache and Pain | 2005年 / 6卷 / 3期

关键词：

Acute treatment; Migraine; Patient preference; Patient satisfaction; Triptans;

D O I：

10.1007/s10194-005-0164-3

中图分类号：

学科分类号：

摘要：

Oral triptans are effective and well tolerated acute treatments for migraine, but clinical differences between them are small and difficult to measure in conventional clinical trials. Patient preference assesses a global measure of efficacy and tolerability,and may be a more sensitive means of distinguishing between these drugs. In a series of studies, patients consistently expressed a clear preference for triptans over their usual non-triptan acute medications, e.g., analgesics and ergotamine. Direct comparator studies of patient preference with oral triptans showed that patients could distinguish between different triptans, and between different formulations of the same triptan. Patients could even distinguish between the three oral doses of sumatriptan. The most frequently provided reasons for preference were speed of response and overall effectiveness. Patient preference is a sensitive clinical trial endpoint and physicians should consider using it when reviewing the efficacy of acute migraine medications. © Springer-Verlag Italia 2005.

引用

页码：112 / 120

页数：8

共 52 条

[21]

Solomon S., Frishberg B., Hu X.H., Et al., Migraine treatment outcomes with rizatriptan in triptan-naïve patients: A naturalistic study, Clin. Ther., 23, pp. 886-890, (2001)

[22]

Robbins L., Triptans vs analgesics: Patient preference, Cephalalgia, 21, (2001)

[23]

Pascual J., Munoz R., Leira R., An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients, Cephalalgia, 21, pp. 680-684, (2001)

[24]

Tfelt-Hansen P., Teall J., Rodriguez F., Et al., Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine, Headache, 38, pp. 748-755, (1998)

[25]

Tfelt-Hansen P., Goldstein J., Malbecq W., Et al., Comparison of rizatriptan and sumatriptan, Headache, 39, pp. 340-341, (1999)

[26]

Bohidar N., Loder E., Guerra F., Et al., Relationship between patient preference for either rizatriptan orally disintegrating tablet (ODT) 10 mg or sumatriptan tablet 50 mg and speed of pain relief, Cephalalgia, 21, (2001)

[27]

Pascual J., Bussone G., Hernandez J.F., Et al., Comparison of preference for rizatriptan 10 mg wafer versus sumatriptan 50 mg tablet in migraine, Eur. Neurol., 45, pp. 275-283, (2001)

[28]

Goadsby P.J., Ferrari M.D., Olesen J., Et al., Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee, Neurology, 54, pp. 156-163, (2000)

[29]

Colman S.S., Brod M.I., Krishnamurthy A., Et al., Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan, Clin. Ther., 23, pp. 127-145, (2001)

[30]

Gerth W.C., McCarroll K.A., Santanello N.C., Et al., Patient satisfaction with rizatriptan versus other triptans: Direct head-to-head comparisons, Int. J. Clin. Pract., 55, pp. 552-556, (2001)

← 1 2 3 4 5 6 →